10-Q 1 lnsr-20240930.htm 10-Q 10-Q
--12-31falseQ3000132035031,8763P1YP1YP1Y4,199P1YP1Y110001320350lnsr:SeriesAConvertiblePreferredStockMember2024-03-310001320350us-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:MaximumMemberlnsr:IncentiveStockOptionsMember2024-01-012024-09-300001320350lnsr:LeasesMember2023-01-012023-09-300001320350us-gaap:CommonStockMember2023-03-3100013203502026-01-012024-09-3000013203502029-01-012024-09-300001320350us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-12-310001320350us-gaap:OtherNoncurrentLiabilitiesMember2023-12-3100013203502023-05-312023-05-310001320350srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2024-07-012024-09-300001320350lnsr:TwoThousandTwentyFourEmploymentInducementIncentiveAwardPlanMembersrt:MaximumMember2024-02-290001320350us-gaap:ServiceMemberus-gaap:CostOfSalesMember2023-01-012023-09-300001320350srt:WeightedAverageMemberus-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001320350us-gaap:PatentedTechnologyMember2024-01-012024-09-300001320350lnsr:SeriesAConvertiblePreferredStockMember2023-09-300001320350us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310001320350us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001320350lnsr:SeriesAWarrantsAndSeriesBWarrantsMember2024-07-012024-09-300001320350lnsr:RestrictedStockAwardsAndUnitsMember2023-01-012023-09-3000013203502024-06-300001320350us-gaap:FairValueInputsLevel3Memberlnsr:SeriesAWarrantsMember2024-09-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeFourMember2024-09-300001320350lnsr:SeriesAWarrantsMember2023-05-310001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeThreeMember2024-01-012024-09-300001320350srt:EuropeMember2023-07-012023-09-3000013203502024-01-012024-09-300001320350us-gaap:RetainedEarningsMember2023-04-012023-06-300001320350lnsr:SeriesAConvertiblePreferredStockMember2023-06-300001320350srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2023-07-012023-09-300001320350lnsr:SeriesAWarrantsAndSeriesBWarrantsMember2024-01-012024-09-300001320350lnsr:TwoThousandTwentyFourEmploymentInducementIncentiveAwardPlanMember2024-01-012024-09-3000013203502024-04-012024-06-300001320350us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2024-09-300001320350us-gaap:CustomerRelationshipsMember2024-01-012024-09-300001320350us-gaap:SeriesAPreferredStockMember2023-01-012023-09-300001320350us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100013203502023-12-310001320350lnsr:SupplyAgreementsMember2024-09-300001320350srt:WeightedAverageMember2023-07-012023-09-300001320350us-gaap:FairValueMeasurementsRecurringMember2024-09-300001320350us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2024-09-3000013203502024-09-300001320350srt:MinimumMemberlnsr:SecuritiesPurchaseAgreementMember2023-05-310001320350us-gaap:SeriesAPreferredStockMember2024-04-012024-06-300001320350lnsr:SeriesARedeemableConvertiblePreferredStockAndSeriesAAndSeriesBWarrantsMember2024-07-012024-09-300001320350us-gaap:ProductMemberus-gaap:CostOfSalesMember2023-07-012023-09-300001320350us-gaap:ServiceMemberus-gaap:CostOfSalesMember2024-07-012024-09-300001320350country:US2024-01-012024-09-300001320350country:KR2023-01-012023-09-300001320350lnsr:NotesAndOtherReceivablesNoncurrentMember2024-09-300001320350us-gaap:SeriesAPreferredStockMember2024-07-012024-09-3000013203502023-01-012023-03-310001320350country:KR2024-07-012024-09-300001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001320350us-gaap:MoneyMarketFundsMember2023-12-310001320350lnsr:IncentiveAwardPlanMember2024-09-300001320350us-gaap:EmployeeStockMember2022-09-300001320350lnsr:NotesAndOtherReceivablesNoncurrentMember2023-12-310001320350srt:EuropeMember2023-01-012023-09-300001320350us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberlnsr:LongTermInvestmentMember2024-09-300001320350us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001320350us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001320350lnsr:LeasesMember2024-01-012024-09-300001320350us-gaap:TrademarksMember2023-12-310001320350us-gaap:EmployeeStockOptionMember2024-07-012024-09-300001320350us-gaap:CommonStockMember2022-12-310001320350srt:WeightedAverageMemberlnsr:RestrictedStockAwardsAndUnitsMember2023-07-012023-09-3000013203502024-10-012024-09-300001320350us-gaap:USTreasuryBillSecuritiesMember2024-09-300001320350lnsr:SeriesBWarrantsMembersrt:WeightedAverageMember2024-07-012024-09-300001320350lnsr:IncentiveStockOptionsAndNonqualifiedStockOptionsMembersrt:MaximumMember2024-01-012024-09-300001320350us-gaap:CommonStockMember2024-01-012024-03-310001320350us-gaap:RetainedEarningsMember2023-01-012023-03-310001320350us-gaap:ServiceMember2024-01-012024-09-300001320350us-gaap:SeriesAPreferredStockMember2024-01-012024-09-300001320350us-gaap:FairValueInputsLevel3Member2024-01-012024-09-300001320350us-gaap:OtherNoncurrentLiabilitiesMember2024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2023-09-300001320350us-gaap:AdditionalPaidInCapitalMember2024-09-300001320350us-gaap:CostOfSalesMemberus-gaap:ProductMember2023-01-012023-09-300001320350lnsr:LeasesMember2024-07-012024-09-300001320350lnsr:SeriesAWarrantsAndSeriesBWarrantsMember2023-07-012023-09-300001320350us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-09-300001320350us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001320350us-gaap:SalesMemberus-gaap:ProductMember2023-01-012023-09-300001320350us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001320350lnsr:IncentiveStockOptionsAndNonqualifiedStockOptionsMemberus-gaap:ShareBasedCompensationAwardTrancheOneMembersrt:MaximumMember2024-01-012024-09-3000013203502024-03-310001320350us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300001320350lnsr:OtherGeographicalRegionMember2023-01-012023-09-300001320350srt:WeightedAverageMemberlnsr:SeriesAWarrantsMember2024-07-012024-09-300001320350lnsr:IncentiveStockOptionsAndNonqualifiedStockOptionsMembersrt:MinimumMember2024-01-012024-09-300001320350us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300001320350us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001320350lnsr:SeriesAConvertiblePreferredStockMember2024-09-300001320350lnsr:AsiaExcludingSouthKoreaMember2024-07-012024-09-300001320350us-gaap:RetainedEarningsMember2022-12-310001320350us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001320350lnsr:SeriesAConvertiblePreferredStockMember2023-04-012023-06-300001320350us-gaap:ProductMemberus-gaap:CostOfSalesMember2024-01-012024-09-300001320350us-gaap:FairValueInputsLevel1Member2023-12-310001320350us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001320350srt:MinimumMember2024-01-012024-09-300001320350us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001320350us-gaap:FairValueInputsLevel3Memberlnsr:SeriesAWarrantsMember2023-12-3100013203502024-10-310001320350srt:WeightedAverageMemberus-gaap:SeriesAPreferredStockMember2023-07-012023-09-300001320350lnsr:RestrictedStockAwardsAndUnitsMember2024-07-012024-09-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeOneMember2024-09-3000013203502023-01-012023-09-300001320350lnsr:TwoThousandTwentyIncentiveAwardPlanMember2024-01-012024-09-300001320350us-gaap:ShareBasedCompensationAwardTrancheTwoMembersrt:MinimumMemberlnsr:IncentiveStockOptionsMember2024-01-012024-09-300001320350us-gaap:CertificatesOfDepositMember2023-12-310001320350lnsr:SeriesAWarrantsAndSeriesBWarrantsMember2023-01-012023-09-300001320350us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001320350us-gaap:ProductMember2023-07-012023-09-300001320350us-gaap:CommonStockMember2023-12-310001320350us-gaap:CustomerRelationshipsMember2024-09-300001320350srt:WeightedAverageMember2024-07-012024-09-300001320350country:KR2024-01-012024-09-300001320350us-gaap:CertificatesOfDepositMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001320350us-gaap:FairValueInputsLevel3Memberlnsr:SeriesBWarrantsMember2023-12-310001320350lnsr:SeriesBWarrantsMembersrt:WeightedAverageMember2024-01-012024-09-300001320350us-gaap:PatentedTechnologyMember2023-12-310001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeFourMember2024-01-012024-09-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeThreeMember2024-09-300001320350us-gaap:USTreasuryBillSecuritiesMember2023-12-310001320350us-gaap:RetainedEarningsMember2024-04-012024-06-300001320350us-gaap:StockOptionMember2024-01-012024-09-300001320350srt:WeightedAverageMemberlnsr:RestrictedStockAwardsAndUnitsMember2024-07-012024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2023-06-300001320350lnsr:TwoThousandTwentyIncentiveAwardPlanMember2020-07-302020-07-310001320350us-gaap:PatentedTechnologyMember2022-12-310001320350us-gaap:AdditionalPaidInCapitalMember2022-12-310001320350us-gaap:AdditionalPaidInCapitalMember2023-12-310001320350us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001320350us-gaap:AdditionalPaidInCapitalMember2023-03-310001320350us-gaap:FairValueInputsLevel3Memberlnsr:SeriesBWarrantsMember2024-09-300001320350us-gaap:FairValueInputsLevel1Member2024-09-300001320350us-gaap:TrademarksMember2024-01-012024-09-300001320350lnsr:TwoThousandTwentyIncentiveAwardPlanMember2024-09-300001320350us-gaap:RestrictedStockUnitsRSUMemberlnsr:IncentiveAwardPlanMember2024-01-012024-09-300001320350srt:MaximumMemberus-gaap:CustomerRelationshipsMember2024-09-300001320350lnsr:OtherGeographicalRegionMember2024-01-012024-09-300001320350us-gaap:FairValueInputsLevel3Member2023-12-310001320350us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001320350lnsr:IncentiveAwardPlanMember2024-01-012024-09-300001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeFiveMember2024-09-300001320350us-gaap:RetainedEarningsMember2023-03-310001320350us-gaap:CertificatesOfDepositMember2024-09-300001320350srt:MaximumMember2024-01-012024-09-300001320350lnsr:IncentiveAwardPlanMember2023-12-310001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-3000013203502023-07-012023-09-300001320350lnsr:SeriesARedeemableConvertiblePreferredStockAndSeriesAAndSeriesBWarrantsMember2023-07-012023-09-300001320350us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2024-09-3000013203502025-01-012024-09-300001320350srt:WeightedAverageMemberlnsr:SeriesAWarrantsMember2024-01-012024-09-300001320350us-gaap:RestrictedStockUnitsRSUMemberlnsr:IncentiveAwardPlanMember2024-09-300001320350us-gaap:RetainedEarningsMember2024-06-300001320350us-gaap:RestrictedStockUnitsRSUMemberlnsr:IncentiveAwardPlanMember2023-12-310001320350lnsr:TwoThousandTwentyIncentiveAwardPlanMember2020-07-310001320350us-gaap:ServiceMemberus-gaap:CostOfSalesMember2024-01-012024-09-300001320350srt:WeightedAverageMemberus-gaap:SeriesAPreferredStockMember2024-07-012024-09-300001320350srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2023-01-012023-09-300001320350us-gaap:EmployeeStockMember2024-01-012024-09-300001320350us-gaap:FairValueInputsLevel3Memberlnsr:SeriesAWarrantsMember2024-01-012024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2024-06-300001320350us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001320350us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-09-300001320350us-gaap:EmployeeStockOptionMember2024-01-012024-09-300001320350us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMemberlnsr:LongTermInvestmentMember2023-12-310001320350us-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001320350us-gaap:CommonStockMember2023-09-3000013203502023-01-012023-12-3100013203502022-12-310001320350us-gaap:SalesMemberus-gaap:ProductMember2024-07-012024-09-300001320350srt:WeightedAverageMemberlnsr:SeriesAWarrantsMember2023-01-012023-09-300001320350us-gaap:TrademarksMember2024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001320350us-gaap:RetainedEarningsMember2024-09-300001320350lnsr:USGovernmentSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001320350srt:WeightedAverageMemberlnsr:RestrictedStockAwardsAndUnitsMember2024-01-012024-09-300001320350lnsr:SeriesAConvertiblePreferredStockMember2024-04-012024-06-300001320350lnsr:AsiaExcludingSouthKoreaMember2023-01-012023-09-300001320350lnsr:InternationalDistributionAgreementMember2024-01-012024-03-310001320350us-gaap:StockOptionMember2024-09-300001320350us-gaap:ProductMember2024-01-012024-09-300001320350srt:EuropeMember2024-01-012024-09-3000013203502028-01-012024-09-300001320350us-gaap:PatentedTechnologyMember2024-09-300001320350country:KR2023-07-012023-09-300001320350us-gaap:RetainedEarningsMember2023-07-012023-09-300001320350lnsr:SeriesBWarrantsMember2023-05-310001320350lnsr:RestrictedStockAwardsAndUnitsMember2024-01-012024-09-3000013203502023-09-300001320350us-gaap:CommonStockMember2024-07-012024-09-300001320350srt:EuropeMember2024-07-012024-09-300001320350srt:MinimumMember2024-09-300001320350lnsr:AsiaExcludingSouthKoreaMember2024-01-012024-09-3000013203502023-03-3100013203502024-07-012024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001320350us-gaap:CommonStockMember2024-06-300001320350lnsr:OtherGeographicalRegionMember2023-07-012023-09-300001320350srt:WeightedAverageMemberlnsr:RestrictedStockAwardsAndUnitsMember2023-01-012023-09-300001320350us-gaap:CommonStockMember2023-06-300001320350us-gaap:ServiceMember2024-07-012024-09-300001320350us-gaap:SeriesAPreferredStockMember2023-07-012023-09-300001320350us-gaap:SeriesAPreferredStockMemberlnsr:SecuritiesPurchaseAgreementMember2023-05-312023-05-3100013203502024-01-012024-03-3100013203502023-06-300001320350us-gaap:RetainedEarningsMember2023-06-300001320350lnsr:RestrictedStockAwardsAndUnitsMember2023-07-012023-09-300001320350us-gaap:RetainedEarningsMember2024-07-012024-09-300001320350us-gaap:ProductMember2023-01-012023-09-300001320350us-gaap:CommonStockMember2023-01-012023-03-310001320350us-gaap:CommonStockMember2023-04-012023-06-300001320350srt:WeightedAverageMemberus-gaap:SeriesAPreferredStockMember2024-01-012024-09-300001320350country:US2023-01-012023-09-3000013203502027-01-012024-09-300001320350us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001320350us-gaap:RetainedEarningsMember2024-01-012024-03-310001320350us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001320350srt:MaximumMember2024-09-300001320350srt:WeightedAverageMember2023-01-012023-09-300001320350us-gaap:RetainedEarningsMember2023-12-310001320350us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2024-09-300001320350us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001320350us-gaap:ProductMember2024-07-012024-09-300001320350us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-09-300001320350us-gaap:CommonStockMember2023-07-012023-09-300001320350us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001320350us-gaap:FairValueMeasurementsRecurringMember2023-12-310001320350lnsr:IncentiveAwardPlanMember2023-01-012023-12-310001320350lnsr:USGovernmentSecuritiesMemberus-gaap:FairValueInputsLevel1Member2024-09-300001320350us-gaap:AdditionalPaidInCapitalMember2024-03-310001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001320350us-gaap:FairValueInputsLevel3Memberlnsr:SeriesBWarrantsMember2024-01-012024-09-300001320350lnsr:SeriesAConvertiblePreferredStockMember2024-06-300001320350us-gaap:CommonStockMember2024-04-012024-06-300001320350us-gaap:RetainedEarningsMember2023-09-300001320350us-gaap:RestrictedStockUnitsRSUMember2024-09-300001320350country:US2024-07-012024-09-300001320350lnsr:SeriesARedeemableConvertiblePreferredStockAndSeriesAAndSeriesBWarrantsMember2023-01-012023-09-300001320350lnsr:SeriesARedeemableConvertiblePreferredStockAndSeriesAAndSeriesBWarrantsMember2024-01-012024-09-300001320350country:US2023-07-012023-09-300001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-3100013203502023-04-012023-06-300001320350lnsr:TwoThousandTwentyIncentiveAwardPlanMember2023-12-310001320350us-gaap:SeriesAPreferredStockMember2024-01-012024-09-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeTwoMember2024-01-012024-09-300001320350us-gaap:ServiceMember2023-07-012023-09-300001320350us-gaap:EmployeeStockMember2024-09-300001320350lnsr:SeriesBWarrantsMembersrt:WeightedAverageMember2023-01-012023-09-300001320350lnsr:OtherGeographicalRegionMember2024-07-012024-09-300001320350us-gaap:CommonStockMember2024-03-310001320350us-gaap:FairValueInputsLevel3Member2024-09-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeOneMember2024-01-012024-09-300001320350lnsr:IncentiveStockOptionsAndNonqualifiedStockOptionsMembersrt:MinimumMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300001320350lnsr:AsiaExcludingSouthKoreaMember2023-07-012023-09-300001320350us-gaap:ServiceMember2023-01-012023-09-300001320350us-gaap:CertificatesOfDepositMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001320350us-gaap:CustomerRelationshipsMember2023-12-310001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeTwoMember2024-09-300001320350lnsr:SeriesAConvertiblePreferredStockMember2023-12-310001320350us-gaap:ProductMemberus-gaap:CostOfSalesMember2024-07-012024-09-300001320350us-gaap:ServiceMemberus-gaap:CostOfSalesMember2023-07-012023-09-300001320350us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel1Member2023-12-310001320350srt:WeightedAverageMember2024-01-012024-09-300001320350lnsr:LeasesMember2023-07-012023-09-300001320350srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2024-01-012024-09-300001320350us-gaap:SalesMemberus-gaap:ProductMember2024-01-012024-09-300001320350us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001320350us-gaap:SalesMemberus-gaap:ProductMember2023-07-012023-09-300001320350lnsr:TwoThousandTwentyFourEmploymentInducementIncentiveAwardPlanMember2024-09-300001320350us-gaap:RetainedEarningsMember2024-03-310001320350us-gaap:MoneyMarketFundsMember2024-09-300001320350us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryBillSecuritiesMember2023-12-310001320350lnsr:SeriesAConvertiblePreferredStockMember2023-01-012023-03-310001320350us-gaap:ShareBasedCompensationAwardTrancheTwoMemberlnsr:IncentiveStockOptionsMember2024-01-012024-09-300001320350lnsr:USGovernmentSecuritiesMember2024-09-300001320350us-gaap:CommonStockMember2024-09-300001320350us-gaap:StockOptionMemberlnsr:ExercisePriceRangeFiveMember2024-01-012024-09-30xbrli:pureiso4217:USDxbrli:sharesxbrli:sharesiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

 

(Mark One)

Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2024

or

Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from to

Commission File Number: 001-39473

 

LENSAR, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

32-0125724

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

2800 Discovery Drive

Orlando, Florida 32826

(Address of principal executive offices and Zip Code)

(888) 536-7271

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, par value $0.01 per share

 

LNSR

 

The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

Accelerated Filer

Non-accelerated filer

 

Smaller reporting company

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes No

As of October 31, 2024, there were 11,614,807 shares of the registrant’s Common Stock outstanding.

 

 


 

Table of Contents

 

 

Page

 

Forward-Looking Statements

iii

 

Risk Factor Summary

v

PART I – FINANCIAL INFORMATION

1

Item 1.

Financial Statements

1

 

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

1

 

Condensed Balance Sheets (Unaudited)

2

 

Condensed Statements of Cash Flows (Unaudited)

3

 

Condensed Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders’ Equity (Unaudited)

5

 

Notes to the Condensed Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

24

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

33

Item 4.

Controls and Procedures

34

PART II – OTHER INFORMATION

35

Item 1.

Legal Proceedings

35

Item 1A.

Risk Factors

35

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

75

Item 3.

Defaults Upon Senior Securities

75

Item 4.

Mine Safety Disclosures

75

Item 5.

Other Information

75

Item 6.

Exhibits

77

Signatures

78

 

 


 

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (the “Quarterly Report”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report, including without limitation statements regarding our business model and strategic plans for our products, technologies and business, including our implementation thereof; the impact on our business, financial condition and results of operation from macroeconomic conditions; the timing of and our ability to obtain and maintain regulatory approvals and certifications; our expectations about our ability to successfully commercialize and further develop our next generation system, the ALLY Robotic Cataract Laser System™ (“ALLY System”), and the timing thereof; the ALLY System's performance and market impact; the sufficiency of our cash and cash equivalents; industry trends and conditions impacting various markets in which we operate; and the plans and objectives of management for future operations and capital expenditures are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Without limiting the foregoing, in some cases, you can identify forward-looking statements by terms such as “aim”, “may,” “will,” “should,” “expect,” “exploring,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “seeks,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements.

Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those identified in Part I. Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Part II. Item 1A. “Risk Factors” in this Quarterly Report. These risks and uncertainties include, but are not limited to:

our history of operating losses and ability to achieve or sustain profitability;
our ability to develop, receive and maintain regulatory clearance or certification of and successfully commercialize the ALLY System and to maintain our LENSAR Laser System (“LLS”) (collectively the “Systems”);
the impact to our business, financial condition, results of operations and our suppliers and distributors as a result of global macroeconomic conditions;
the willingness of patients to pay the price difference for our products compared to a standard cataract procedure covered by Medicare or other insurance;
our ability to grow our U.S. sales and marketing organization or maintain or grow an effective network of international distributors;
our future capital needs and our ability to raise additional funds on acceptable terms, or at all;
the impact to our business, financial condition and results of operations as a result of a material disruption to the supply or manufacture of our Systems or necessary component parts for such Systems or material inflationary pressures affecting pricing of component parts;
our ability to compete against competitors that have longer operating histories, more established products and greater resources than we do;
our ability to address the numerous risks associated with marketing, selling and leasing our products in markets outside the United States;
the impact to our business, financial condition and results of operations as a result of exposure to the credit risk of our customers;
our ability to accurately forecast customer demand and our inventory levels;
the impact to our business, financial condition and results of operations if we are unable to secure adequate coverage or reimbursement by government or other third-party payors for procedures using our ALLY System or our other products, or changes in such coverage or reimbursement;
the impact to our business, financial condition and results of operations of product liability suits brought against us;

iii


 

risks related to government regulation applicable to our products and operations; and
risks related to our intellectual property and other intellectual property matters.

Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.

You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we have no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Unless otherwise stated or the context requires otherwise, references to “LENSAR,” the “Company,” “we,” “us,” and “our,” refer to LENSAR, Inc.

We own or have registered rights to certain trademarks, trade names, copyrights and other intellectual property used in our business, including LENSAR, the LENSAR logo, Streamline, IntelliAxis, IntelliAxis Refractive Capsulorhexis, ALLY, Intelligent Incisions, Augmented Reality, ALLY Robotic Cataract Laser System, and the ALLY Robotic Cataract Laser System logo, Robotic Laser Cataract Surgery, and the Robotic Laser Cataract Surgery logo, each of which is considered a trademark. All other company names, product names, trade names and trademarks included in this Quarterly Report are trademarks, registered trademarks or trade names of their respective owners.

iv


 

RISK FACTOR SUMMARY

Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. “Risk Factors” in this Quarterly Report. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:

Our results have been in the past, and could be in the future, adversely affected by economic uncertainty or deteriorations in economic conditions.
We expect to incur operating losses for the near-term future and we cannot assure you that we will be able to generate sufficient revenue to achieve or sustain profitability.
We have historically derived our revenue from the sale or lease of our Systems as well as the associated procedure licenses and sale of consumables used in each procedure involving our Systems. The commercial success of our ALLY System will depend upon receipt of additional regulatory clearances or certifications and our ability to maintain and grow significant market acceptance for it.
Our growth depends on our ability to gain regulatory clearances and certifications, as well as our ability to meet production goals for our ALLY System.
Patients may not be willing to pay for the price difference between a standard cataract procedure and an advanced cataract procedure in which a laser system such as ours is used, an increment which is typically not covered by Medicare, private insurance or other third-party payors.
If we are not able to effectively grow our U.S. sales and marketing organization or maintain or grow an effective network of international distributors, our business prospects, results of operations and financial condition could be adversely affected.
Our future capital needs are uncertain and we may need to raise additional funds in the future, and such funds may not be available on acceptable terms or at all.
If the supply or manufacture of our Systems or other products associated with the Systems is materially disrupted, including by supply chain shortages and price increases, it may adversely affect our ability to manufacture products and could negatively affect our operating results.
We currently compete, and expect to compete in the future against other companies, some of which have longer operating histories, more established products or greater resources than we do.
To successfully market, sell and lease our products in markets outside of the United States, we must address many international business risks with which we have limited experience.
Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could harm our business.
We may not receive, or may be delayed in receiving, the necessary clearances, certifications or approvals for our future products, or modifications to our current products, and failure to timely obtain additional clearances, certifications or approvals for our ALLY System and future products or modifications to our current products would adversely affect our ability to grow our business.
Our success will depend on our ability to obtain, maintain and protect our intellectual property rights.

v


 

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

LENSAR, Inc.

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended
September 30,

 

 

Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

 

2024

 

 

2023

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

$

10,578

 

 

$

7,156

 

 

$

27,545

 

 

$

22,191

 

Lease

 

 

1,724

 

 

 

1,524

 

 

 

5,623

 

 

 

4,844

 

Service

 

 

1,237

 

 

 

1,115

 

 

 

3,595

 

 

 

3,024

 

Total revenue

 

 

13,539

 

 

 

9,795

 

 

 

36,763

 

 

 

30,059

 

Cost of revenue (exclusive of amortization)

 

 

 

 

 

 

 

 

 

 

 

 

Product

 

 

4,473

 

 

 

2,933

 

 

 

10,914

 

 

 

8,897

 

Lease

 

 

790

 

 

 

524

 

 

 

2,056

 

 

 

1,514

 

Service

 

 

2,010

 

 

 

1,461

 

 

 

5,050

 

 

 

3,690

 

Total cost of revenue

 

 

7,273

 

 

 

4,918

 

 

 

18,020

 

 

 

14,101

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative expenses

 

 

6,077

 

 

 

5,117

 

 

 

19,657

 

 

 

19,726

 

Research and development expenses

 

 

1,202

 

 

 

1,527

 

 

 

3,994

 

 

 

4,676

 

Amortization of intangible assets

 

 

232

 

 

 

273

 

 

 

738

 

 

 

824

 

Impairment of intangible assets

 

 

 

 

 

 

 

 

3,729

 

 

 

 

Operating loss

 

 

(1,245

)

 

 

(2,040

)

 

 

(9,375

)

 

 

(9,268

)

Other (expense) income

 

 

 

 

 

 

 

 

 

 

 

 

Change in fair value of warrant liabilities

 

 

(410

)

 

 

4,343

 

 

 

(3,838

)

 

 

(1,654

)

Other income, net

 

 

153

 

 

 

265

 

 

 

511

 

 

 

465

 

Net (loss) income

 

 

(1,502

)

 

 

2,568

 

 

 

(12,702

)

 

 

(10,457

)

Other comprehensive (loss) income

 

 

 

 

 

 

 

 

 

 

 

 

Change in unrealized loss on investments

 

 

21

 

 

 

 

 

 

11

 

 

 

 

Net (loss) income and comprehensive (loss) income

 

$

(1,481

)

 

$

2,568

 

 

$

(12,691

)

 

$

(10,457

)

Net (loss) earnings per common share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

(0.13

)

 

$

0.13

 

 

$

(1.11

)

 

$

(0.96

)

Diluted

 

$

(0.13

)

 

$

(0.23

)

 

$

(1.11

)

 

$

(0.96

)

Weighted-average number of common shares used in calculation of net (loss) earnings per share:

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

11,604

 

 

 

11,102

 

 

 

11,481

 

 

 

10,881

 

Diluted

 

 

11,604

 

 

 

11,956

 

 

 

11,481

 

 

 

10,881

 

 

The accompanying notes are an integral part of these condensed financial statements

1


 

LENSAR, Inc.

CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands, except per share amounts)

 

 

 

September 30, 2024

 

 

December 31, 2023

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

10,442

 

 

$

20,621

 

Short-term investments

 

 

7,638

 

 

 

3,443

 

Accounts receivable, net of allowance of $39 and $62, respectively

 

 

4,373

 

 

 

4,001

 

Notes receivable, net of allowance of $7 and $7, respectively

 

 

352

 

 

 

323

 

Inventories

 

 

14,892

 

 

 

15,689

 

Prepaid and other current assets

 

 

1,705

 

 

 

2,367

 

Total current assets

 

 

39,402

 

 

 

46,444

 

Property and equipment, net

 

 

677

 

 

 

679

 

Equipment under lease, net

 

 

12,303

 

 

 

7,459

 

Long-term investments

 

 

494

 

 

 

492

 

Notes and other receivables, long-term, net of allowance of $20 and $26, respectively

 

 

952

 

 

 

1,279

 

Intangible assets, net

 

 

6,344

 

 

 

11,025

 

Other assets

 

 

1,847

 

 

 

2,207

 

Total assets

 

$

62,019

 

 

$

69,585

 

Liabilities, redeemable convertible preferred stock, and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

3,867

 

 

$

4,007

 

Accrued liabilities

 

 

5,800

 

 

 

5,717

 

Deferred revenue

 

 

1,437

 

 

 

1,349

 

Operating lease liabilities

 

 

574

 

 

 

559

 

Total current liabilities

 

 

11,678

 

 

 

11,632

 

Long-term operating lease liabilities

 

 

1,319

 

 

 

1,750

 

Warrant liabilities

 

 

12,295

 

 

 

8,457

 

Other long-term liabilities

 

 

205

 

 

 

570

 

Total liabilities

 

 

25,497

 

 

 

22,409

 

Commitments and contingencies (Note 10)

 

 

 

 

 

 

Series A Redeemable Convertible Preferred Stock, par value $0.01 per share, 20 shares authorized at September 30, 2024 and December 31, 2023; 20 shares issued and outstanding at September 30, 2024 and December 31, 2023; aggregate liquidation preference of $20,000 at September 30, 2024 and December 31, 2023

 

 

13,784

 

 

 

13,747

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, par value $0.01 per share, 9,980 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023

 

 

 

 

 

 

Common stock, par value $0.01 per share, 150,000 shares authorized at September 30, 2024 and December 31, 2023; 11,612 and 11,327 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively

 

 

116

 

 

 

113

 

Additional paid-in capital

 

 

147,200

 

 

 

145,203

 

Accumulated other comprehensive income

 

 

15

 

 

 

4

 

Accumulated deficit

 

 

(124,593

)

 

 

(111,891

)

Total stockholders’ equity

 

 

22,738

 

 

 

33,429

 

Total liabilities, redeemable convertible preferred stock, and stockholders’ equity

 

$

62,019

 

 

$

69,585

 

 

The accompanying notes are an integral part of these condensed financial statements

2


 

LENSAR, Inc.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended

 

 

 

September 30,

 

 

 

2024

 

 

2023

 

Cash flows from operating activities

 

 

 

 

 

 

Net loss

 

$

(12,702

)

 

$

(10,457

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

Depreciation

 

 

2,087

 

 

 

1,767

 

Amortization of intangible assets

 

 

738

 

 

 

824

 

Impairment of intangible assets

 

 

3,729

 

 

 

 

Non-cash operating lease cost

 

 

404

 

 

 

400

 

Provision for expected credit losses

 

 

(5

)

 

 

(4

)

Write-down of inventory

 

 

134

 

 

 

66

 

Stock-based compensation expense

 

 

2,003

 

 

 

4,723

 

Change in fair value of warrant liabilities

 

 

3,838

 

 

 

1,654

 

Amortization on investments, net

 

 

(185

)

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable

 

 

(374

)

 

 

2,212

 

Notes receivable

 

 

305

 

 

 

(769

)

Prepaid and other current assets

 

 

660

 

 

 

(1,069

)

Inventories

 

 

(6,113

)

 

 

(7,940

)

Accounts payable

 

 

(139

)

 

 

(1,489

)

Accrued liabilities

 

 

212

 

 

 

626

 

Deferred revenue

 

 

(61

)

 

 

611

 

Operating lease liabilities

 

 

(416

)

 

 

(402

)

Other

 

 

(47

)

 

 

68

 

Net cash used in operating activities

 

 

(5,932

)

 

 

(9,179

)

Cash flows from investing activities

 

 

 

 

 

 

Purchase of property and equipment

 

 

(153

)

 

 

(191

)

Purchase of investments

 

 

(10,245

)

 

 

 

Investment maturities

 

 

6,245

 

 

 

 

Net cash used in investing activities

 

 

(4,153

)

 

 

(191

)

Cash flows from financing activities

 

 

 

 

 

 

Proceeds from issuance of common stock through option exercises

 

 

21

 

 

 

 

Proceeds from issuance of common stock under employee stock purchase plan

 

 

170

 

 

 

181

 

Net settlement of stock-based compensation awards

 

 

(187

)

 

 

(52

)

Proceeds from issuance of redeemable convertible preferred stock, net of offering costs

 

 

 

 

 

13,882

 

Proceeds from issuance of warrants

 

 

 

 

 

5,605

 

Payment of accrued offering costs allocable to preferred stock

 

 

(98

)

 

 

 

Net cash (used in) provided by financing activities

 

 

(94

)

 

 

19,616

 

Net (decrease) increase in cash and cash equivalents

 

 

(10,179

)

 

 

10,246

 

Cash and cash equivalents at beginning of the period

 

 

20,621

 

 

 

14,674

 

Cash and cash equivalents at end of the period

 

$

10,442

 

 

$

24,920

 

 

The accompanying notes are an integral part of these condensed financial statements

3


 

LENSAR, Inc.

CONDENSED STATEMENTS OF CASH FLOWS, continued

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended
September 30,

 

 

 

2024

 

 

2023

 

Supplemental cash flow information

 

 

 

 

 

 

Cash paid for taxes

 

$

22

 

 

$

18

 

 

 

 

 

 

 

 

Supplemental schedule of non-cash investing and financing activities

 

 

 

 

 

 

Transfer from Inventories to Equipment under lease, net

 

$

6,775

 

 

$

2,879

 

Transfer from (to) Inventories to (from) Property and equipment, net

 

$

 

 

$

(746

)

Accrued offering costs

 

$

37

 

 

$

(135

)

 

The accompanying notes are an integral part of these condensed financial statements

4


 

LENSAR, Inc.

CONDENSED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

(Unaudited)

(In thousands)

 

 

 

Series A

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Redeemable Convertible

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Other

 

 

Total

 

 

 

Preferred Stock

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance as of December 31, 2023

 

 

20

 

 

$

13,747

 

 

 

 

11,327

 

 

$

113

 

 

$

145,203

 

 

$

(111,891

)

 

$

4

 

 

$

33,429

 

Exercise of stock options under the Incentive Plans

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

5

 

Issuance of common stock under the Incentive Plans, net of forfeitures

 

 

 

 

 

 

 

 

 

66

 

 

 

1

 

 

 

(90

)

 

 

 

 

 

 

 

 

(89

)

Stock-based compensation under the Incentive Plans

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

652

 

 

 

 

 

 

 

 

 

652

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(2,157

)

 

 

 

 

 

(2,157

)

Change in unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5

)

 

 

(5

)

Balance as of March 31, 2024

 

 

20

 

 

 

13,747

 

 

 

 

11,395

 

 

 

114

 

 

 

145,770

 

 

 

(114,048

)

 

 

(1

)

 

 

31,835

 

Exercise of stock options under the Incentive Plans

 

 

 

 

 

 

 

 

 

2

 

 

 

 

 

 

5

 

 

 

 

 

 

 

 

 

5

 

Issuance of common stock under the Incentive Plans, net of forfeitures

 

 

 

 

 

 

 

 

 

67

 

 

 

1

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

Issuance of common stock under the 2020 ESPP

 

 

 

 

 

 

 

 

 

80

 

 

 

 

 

 

170

 

 

 

 

 

 

 

 

 

170

 

Stock-based compensation under the Incentive Plans

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

683

 

 

 

 

 

 

 

 

 

683

 

Series A Redeemable Convertible Preferred Stock offering costs accrual release

 

 

 

 

 

37

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,043

)

 

 

 

 

 

(9,043

)

Change in unrealized loss on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(5

)

 

 

(5

)

Balance as of June 30, 2024

 

 

20

 

 

 

13,784

 

 

 

 

11,544

 

 

 

115

 

 

 

146,627

 

 

 

(123,091

)

 

 

(6

)

 

 

23,645

 

Exercise of stock options under the Incentive Plans

 

 

 

 

 

 

 

 

 

5

 

 

 

 

 

 

11

 

 

 

 

 

 

 

 

 

11

 

Issuance of common stock under the Incentive Plans, net of forfeitures

 

 

 

 

 

 

 

 

 

63

 

 

 

1

 

 

 

(106

)

 

 

 

 

 

 

 

 

(105

)

Stock-based compensation under the Incentive Plans

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

668

 

 

 

 

 

 

 

 

 

668

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1,502

)

 

 

 

 

 

(1,502

)

Change in unrealized gain on investments

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

21

 

 

 

21

 

Balance as of September 30, 2024

 

 

20

 

 

$

13,784

 

 

 

 

11,612

 

 

$

116

 

 

$

147,200

 

 

$

(124,593

)

 

$

15

 

 

$

22,738

 

 

The accompanying notes are an integral part of these condensed financial statements

 

5


 

LENSAR, Inc.

CONDENSED STATEMENTS OF CHANGES IN REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY, continued

(Unaudited)

(In thousands)

 

 

 

Series A

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Redeemable Convertible

 

 

 

 

 

 

 

 

 

Additional

 

 

 

 

 

Other

 

 

Total

 

 

 

Preferred Stock

 

 

 

Common Stock

 

 

Paid-in

 

 

Accumulated

 

 

Comprehensive

 

 

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income

 

 

Equity

 

Balance as of December 31, 2022

 

 

 

 

$

 

 

 

 

11,093

 

 

$

111

 

 

$

139,381

 

 

$

(97,508

)

 

$

 

 

$

41,984

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,726

 

 

 

 

 

 

 

 

 

1,726

 

Issuance of common stock under the 2020 Plan, net of forfeitures

 

 

 

 

 

 

 

 

 

15

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock awards cancelled

 

 

 

 

 

 

 

 

 

(5

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(4,272

)

 

 

 

 

 

(4,272

)

Balance at March 31, 2023

 

 

 

 

 

 

 

 

 

11,103

 

 

 

111

 

 

 

141,107

 

 

 

(101,780

)

 

 

 

 

 

39,438

 

Issuance of Series A Redeemable Convertible Preferred Stock, net of offering costs of $649

 

 

20

 

 

 

13,747

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,824

 

 

 

 

 

 

 

 

 

1,824

 

Issuance of common stock under the 2020 ESPP

 

 

 

 

 

 

 

 

 

71

 

 

 

1

 

 

 

180

 

 

 

 

 

 

 

 

 

181

 

Issuance of common stock under the 2020 Plan

 

 

 

 

 

 

 

 

 

26

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock awards cancelled

 

 

 

 

 

 

 

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(8,753

)

 

 

 

 

 

(8,753

)

Balance as of June 30, 2023

 

 

20

 

 

 

13,747

 

 

 

 

11,199

 

 

 

112

 

 

 

143,111

 

 

 

(110,533

)

 

$

 

 

$

32,690

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

1,173

 

 

 

 

 

 

 

 

 

1,173

 

Issuance of common stock under the 2020 Plan, net of forfeitures

 

 

 

 

 

 

 

 

 

47

 

 

 

 

 

 

(48

)

 

 

 

 

 

 

 

 

(48

)

Net income